Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.

Breast J · 2020 · PMC7496313 · PMID 31782589

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

NJ, USA 10.13039/501100003769 Additional exploratory pooled post hoc analysis for patients receiving 0‐6 prior lines of therapy showed a trend for higher OS in patients treated with eribulin compared with control (Table 2 ), and this trend was emphasized in those patients with 0‐3 prior lines of therapy compared with those who had been more heavily pretreated.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.